Evaluation of the Cardiovascular Effects of the MAS in the Treatment of Obstructive Sleep Apnea

Evaluation of the Overall Effectiveness Including Cardiovascular Effects of the Custom-made, Titratable Duoblock Flex SomnoDent® MAS in the Treatment of Obstructive Sleep Apnea

In this prospective trial 50 patients, diagnosed with moderate to severe obstructive sleep apnea (OSA) (AHI > 15/h sleep) will be included and treated with mandibular advancement devices (MAD). These patients will undergo cardiovascular examination; echocardiography and 24h-blood pressure monitoring, on top of the normal clinical evaluation of OSA patients. These cardiovascular examinations will take place before and during MAD therapy.

Inclusion Criteria:

• AHI > 15 events/hour
• No other active OSA therapy in the 3 months preceding inclusion
• Willing to participate after informed consent
• Positive advice on OAT after DISE

Exclusion Criteria:

• Insufficient teeth to support the device
• Periodontal problems including tooth mobility
• Active temporomandibular joint dysfunction
• Limited maximum protrusive capacity (< 6 mm)